Algeta targets breast cancer and angiogenesis through research pact with Affibody
Oslo – Norwegian targeted cancer radiotherapy specialist Algeta ASA has stepped into a global exclusive research, development and commercialisation agreement with Swedish Affibody AB (Stockholm), aimed at targeting its alpha particle-emitting thorium-227 radionuclides against Her2neu- and PDGFRβ-overexpressing tumours. Under the terms of the agreement Algeta and Affibody will determine whether two 6.5 kDa antibody mimetics, which target Her2 and PDGFRβ, can be effective carriers targeting molecules for Algeta’s thorium-227 payload. If the initial research collaboration is successful, Algeta will be responsible for all preclinical and clinical development of any development candidates that result from this collaboration, and commercialization. The companies did not publish any financial details about upfront fees, milestones or other payments to Affibody. With the agreement, Algeta will also gain access to Affibody’s Albumod platform which is designed to prevent the normally rapid renal clearance of radiolabelled Affibodies. Researchers recently published details on strategies to prolong plasma half life of radiolabelled Affibody conjugates. Algeta hopes 1st targeted radiotherapy can overcome drug-resistance mechanisms. In addition, tumour cells adjacent to those bound by the alpha-pharmaceutical may also be destroyed even if they do not bind the drug themselves. The short range of the alpha particle means that damage to healthy cells and side effects may be minimized.